Subscribe to Entrepreneur for $5

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

Eli Lilly (LLY) closed at $276.22 in the latest trading session, marking a -0.37% move from the prior day.

This story originally appeared on Zacks

Eli Lilly (LLY) closed the most recent trading day at $276.22, moving -0.37% from the previous trading session. This change lagged the S&P 500's daily loss of 0.26%. At the same time, the Dow lost 0.16%, and the tech-heavy Nasdaq lost 0.04%.

- Zacks

Coming into today, shares of the drugmaker had gained 11.85% in the past month. In that same time, the Medical sector gained 5.77%, while the S&P 500 gained 4.82%.

Investors will be hoping for strength from Eli Lilly as it approaches its next earnings release. In that report, analysts expect Eli Lilly to post earnings of $2.50 per share. This would mark a year-over-year decline of 9.09%. Meanwhile, our latest consensus estimate is calling for revenue of $7.56 billion, up 1.61% from the prior-year quarter.

LLY's full-year Zacks Consensus Estimates are calling for earnings of $8.18 per share and revenue of $28.29 billion. These results would represent year-over-year changes of +3.15% and +15.3%, respectively.

Investors should also note any recent changes to analyst estimates for Eli Lilly. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.79% higher within the past month. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).

Valuation is also important, so investors should note that Eli Lilly has a Forward P/E ratio of 33.9 right now. This represents a premium compared to its industry's average Forward P/E of 13.83.

Investors should also note that LLY has a PEG ratio of 2.13 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.11 based on yesterday's closing prices.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 167, which puts it in the bottom 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow LLY in the coming trading sessions, be sure to utilize

Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?

From inception in 2012 through November, the Zacks Top 10 Stocks gained an impressive +962.5% versus the S&P 500’s +329.4%. Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.

Be First To New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


Eli Lilly and Company (LLY): Free Stock Analysis Report


To read this article on click here.